7779 Stock Overview Researches, develops, produces, sell, leases, and maintains robotic equipment and systems for medical and welfare in Japan, the United States, Europe, the Middle East, Africa, and the Asia Pacific countries. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
CYBERDYNE Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for CYBERDYNE Historical stock prices Current Share Price JP¥174.00 52 Week High JP¥239.00 52 Week Low JP¥155.00 Beta 0.46 1 Month Change 10.13% 3 Month Change -3.87% 1 Year Change -20.55% 3 Year Change -52.46% 5 Year Change -67.05% Change since IPO -81.88%
Recent News & Updates
CYBERDYNE Inc. to Report Q3, 2025 Results on Feb 13, 2025 Jan 09
Consensus EPS estimates upgraded to JP¥2.22 loss Dec 12
CYBERDYNE Inc. Announces on the New Product Medical Vital Sensor Cyvis M100 Dec 10
Consensus EPS estimates upgraded to JP¥2.60 loss Nov 21
Second quarter 2025 earnings released: JP¥1.50 loss per share (vs JP¥4.42 loss in 2Q 2024) Nov 19
CYBERDYNE Inc. to Report First Half, 2025 Results on Nov 14, 2024 Sep 20 See more updates
CYBERDYNE Inc. to Report Q3, 2025 Results on Feb 13, 2025 Jan 09
Consensus EPS estimates upgraded to JP¥2.22 loss Dec 12
CYBERDYNE Inc. Announces on the New Product Medical Vital Sensor Cyvis M100 Dec 10
Consensus EPS estimates upgraded to JP¥2.60 loss Nov 21
Second quarter 2025 earnings released: JP¥1.50 loss per share (vs JP¥4.42 loss in 2Q 2024) Nov 19
CYBERDYNE Inc. to Report First Half, 2025 Results on Nov 14, 2024 Sep 20
First quarter 2025 earnings released: EPS: JP¥0.052 (vs JP¥1.56 in 1Q 2024) Aug 18
Consensus estimates of losses per share improve by 61% Aug 17
Now 21% overvalued after recent price rise Jul 17
Full year 2024 earnings: EPS and revenues miss analyst expectations Jun 28
Forecast breakeven date pushed back to 2026 Jun 25
CYBERDYNE Inc. to Report Q1, 2025 Results on Aug 14, 2024 Jun 06
New minor risk - Share price stability Jun 04
Full year 2024 earnings: EPS and revenues miss analyst expectations May 20 U.S. FDA Becomes the world's First to Clear Smaller Model of Medical HAL and Expanded Indication for Cerebral Palsy
U.S. FDA Becomes the world's First to Clear Smaller Model of Medical HAL and Expanded Indication for Cerebral Palsy May 16
Price target decreased by 21% to JP¥320 Mar 27
CYBERDYNE Inc. to Report Fiscal Year 2024 Results on May 15, 2024 Mar 09
Third quarter 2024 earnings released: JP¥1.65 loss per share (vs JP¥0.93 loss in 3Q 2023) Feb 16
CYBERDYNE Inc. to Report Q3, 2024 Results on Feb 14, 2024 Dec 27
Consensus EPS estimates fall by 463%, revenue upgraded Dec 16
Forecast breakeven date pushed back to 2026 Dec 15
Second quarter 2024 earnings released: JP¥4.42 loss per share (vs JP¥0.13 profit in 2Q 2023) Nov 18 Nov 17
CYBERDYNE Inc. to Report Q2, 2024 Results on Nov 14, 2023 Oct 05
CYBERDYNE Inc. to Report First Half, 2024 Results on Nov 14, 2023 Sep 16
First quarter 2024 earnings released: EPS: JP¥1.56 (vs JP¥1.12 in 1Q 2023) Aug 15
New minor risk - Share price stability Jul 13
CYBERDYNE Inc. to Report Q1, 2024 Results on Aug 14, 2023 Jul 07
Consensus EPS estimates fall by 783% Jun 21
Forecast breakeven date pushed back to 2025 Jun 01
Forecast breakeven date moved forward to 2024 May 26
Forecast breakeven date moved forward to 2024 May 22
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind May 18
Forecast breakeven date pushed back to 2026 May 18
Consensus EPS estimates fall by 449%, revenue upgraded May 17
CYBERDYNE Inc., Annual General Meeting, Jun 22, 2023 May 16
CYBERDYNE Inc. to Report Fiscal Year 2023 Results on May 15, 2023 Feb 18
Third quarter 2023 earnings released: JP¥0.93 loss per share (vs JP¥0.74 loss in 3Q 2022) Feb 15
CYBERDYNE Inc. to Report Q3, 2023 Results on Feb 14, 2023 Jan 07
Cyberdyne Inc. Announces Yuzo Toda Passed Away on December 27, 2022, and Retired from the Position of Director on the Same Day Jan 06
Consensus EPS estimates increase by 353% Dec 08
Price target decreased to JP¥560 Nov 16
Less than half of directors are independent Nov 16
Consensus forecasts updated Aug 24
Price target decreased to JP¥780 Aug 23
CYBERDYNE Inc. to Report First Half, 2023 Results on Nov 14, 2022 Aug 16
First quarter 2023 earnings released: EPS: JP¥1.13 (vs JP¥1.28 loss in 1Q 2022) Aug 14
CYBERDYNE Inc. to Report Q1, 2023 Results on Aug 12, 2022 May 17
Full year 2022 earnings: EPS and revenues exceed analyst expectations May 16
CYBERDYNE Inc., Annual General Meeting, Jun 30, 2022 May 14
Consensus forecasts updated May 14
Forecast breakeven date pushed back to 2024 May 13
Price target increased to JP¥810 Apr 27
Less than half of directors are independent Apr 27
Now 23% undervalued after recent price drop Mar 07
Price target increased to JP¥843 Mar 02
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 16
CYBERDYNE Inc. to Report Fiscal Year 2022 Results on May 13, 2022 Feb 16
Forecast breakeven date pushed back to 2023 Feb 15
Price target decreased to JP¥745 Nov 24
Second quarter 2022 earnings released: JP¥0.70 loss per share (vs JP¥1.38 profit in 2Q 2021) Nov 15
CYBERDYNE Inc. Announces Medical HAL Single Joint Type Receives Medical Device Approval from Australian Therapeutic Goods Administration, Department of Health Sep 03
CYBERDYNE Inc. (TSE:7779) acquired C2,Inc. Sep 01
First quarter 2022 earnings released: JP¥1.28 loss per share (vs JP¥0.60 loss in 1Q 2021) Aug 18
Cyberdyne Inc. Preliminary Results of Medical Hal Lower Limb Type Stroke Clinical Trial Jun 24
Price target decreased to JP¥845 Jun 02
Full year 2021 earnings released: JP¥0.27 loss per share (vs JP¥0.71 loss in FY 2020) May 17
New 90-day low: JP¥611 Mar 04 CYBERDYNE Inc., Annual General Meeting, Jun 24, 2021
CYBERDYNE Inc Forms Strategic Partnership with Cellsource Co., Ltd Feb 16
Third quarter 2021 earnings released: JP¥0.40 loss per share (vs JP¥0.46 profit in 3Q 2020) Feb 14
Revenue and earnings miss expectations Feb 14
Analysts lower EPS estimates to -JP¥1.36 Feb 13
New 90-day low: JP¥644 Jan 19
CYBERDYNE Inc. to Report Q3, 2021 Results on Feb 12, 2021 Jan 07
CYBERDYNE Inc. Medical Hal Obtains Approval from Singapore Health Science Authority Dec 20
CYBERDYNE Inc. Announces that Stroke Clinical Trial on Medical HAL is Complete Dec 13
Price target raised to JP¥1,075 Dec 01
Cyberdyne Inc. Exports Six Units of Its Wearable Cyborg Hal (Three Units of Lower Limb Type, Two Units of Single Joint Type, One Unit of Lumbar Type) to Institute of Brain & Spine Hospital Nov 19
CYBERDYNE Inc. Obtains a Medical Device Approval for HAL for Medical Use Lower Limb Type Oct 18
Malaysian Public Social Security Organization Expands Cybernics Treatment to 4 Major Sites in Malaysia Oct 17
CYBERDYNE Inc. to Report Q2, 2021 Results on Nov 13, 2020 Oct 10
CYBERDYNE Inc. Announces Marketing Clearance From U.S. FDA for Medical HAL Expands To Stroke And Progressive Neuromuscular Disease Oct 06
CYBERDYNE Inc. to Report Q1, 2021 Results on Aug 14, 2020 Jun 28 Shareholder Returns 7779 JP Medical Equipment JP Market 7D -2.2% 0.5% -0.2% 1Y -20.5% 6.9% 5.0%
See full shareholder returns
Return vs Market: 7779 underperformed the JP Market which returned 5% over the past year.
Price Volatility Is 7779's price volatile compared to industry and market? 7779 volatility 7779 Average Weekly Movement 6.5% Medical Equipment Industry Average Movement 3.4% Market Average Movement 3.5% 10% most volatile stocks in JP Market 7.4% 10% least volatile stocks in JP Market 1.9%
Stable Share Price: 7779's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 7779's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company CYBERDYNE Inc. researches, develops, produces, sell, leases, and maintains robotic equipment and systems for medical and welfare in Japan, the United States, Europe, the Middle East, Africa, and the Asia Pacific countries. The company offers Hybrid Assistive Limb (HAL) for medical use in lower limb and single joint type; non-medical HAL for lower limb, single joint type, and lumbar type; HAL peripherals; cleaning robots; transportation robots for various transportation tasks in factories, offices, and other indoor environments; Acoustic X, a high-speed light pulse LED array light source that enables real time photoacoustic imaging; and CYIN for living support, which is an interface that uses biological information that can be controlled voluntarily outside of muscle activities. It also provides Cybernics Treatment, a treatment that uses HAL to enhance and regenerate the function of the wearer for spinal cord injury, stroke, neuromuscular diseases, etc.; Neuro HALFIT for enhancement of brain-nerve-musculoskeltal system; MTX Neuro HAL Plus to enhance the performance of the athletes’ brain-nerve functions; and Neuro HALFIT at home for enhancement of physical functions.
Show more CYBERDYNE Inc. Fundamentals Summary How do CYBERDYNE's earnings and revenue compare to its market cap? 7779 fundamental statistics Market cap JP¥36.95b Earnings (TTM ) -JP¥1.18b Revenue (TTM ) JP¥4.39b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 7779 income statement (TTM ) Revenue JP¥4.39b Cost of Revenue JP¥2.08b Gross Profit JP¥2.31b Other Expenses JP¥3.49b Earnings -JP¥1.18b
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 12, 2025
Earnings per share (EPS) -5.58 Gross Margin 52.58% Net Profit Margin -26.82% Debt/Equity Ratio 0.3%
How did 7779 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/21 08:46 End of Day Share Price 2025/01/21 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources CYBERDYNE Inc. is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution null null Astris Advisory Japan, K.K. Hidemaru Yamaguchi Citigroup Inc Takahiro Mori Daiwa Securities Co. Ltd.
Show 7 more analysts 
